|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 4.060 USD | +2.53% |
|
+2.78% | -28.40% |
| 08-06 | MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says | MT |
| 08-05 | MannKind Corporation, Q2 2026 Earnings Call, Aug 05, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.31B | - | - | - | ||
| 67.98B | |||||
| 64.94B | |||||
| 27.58B | - | ||||
| 26.06B | - | ||||
| 25.74B |
- Stock Market
- Stocks
- MNKD Stock
- Charts MannKind Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
